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1. Introduction 
The biological membrane, which encloses all living 
cells, is composed of a phospholipid bilayer that hinders 
the entrance and exit of water-soluble solutes, such as ions, 
metabolites and antimicrobial agents. However, a special- 
ized class of integral membrane proteins, called trans- 
porters or carrier proteins, serve to overcome this mem- 
brane barricade by translocating water-soluble solutes 
across the lipid bilayer [56,89]. Life cannot occur without 
membrane carrier proteins. Moreover, when carrier pro- 
teins are faulty in humans, medical problems can arise. For 
example, glucose-galactose malabsorption is a serious dis- 
ease in which a mutation has occurred in the Na+/glucose 
carrier of the small intestine and the absorption of glucose 
and galactose is severely impaired [102]. A defect in a 
chloride ion channel results in cystic fibrosis [48]. 
1.1. The chemiosmotic hypothesis 
In the early 1960s, Peter Mitchell formulated his now 
famous chemiosmotic theory, in which an electrochemical 
gradient of protons, generated by the respiratory chain, 
was the energetic driving force for the synthesis of ATP 
[78]. He later predicted that the lactose carrier of Es- 
cherichia coli accomplished obligatory coupling between 
proton and sugar movement across the membrane and that 
the downhill entry of protons resulted in sugar entry and 
accumulation [79]. This important ion gradient-dependent 
biological process is known as secondary active transport, 
distinguished from primary active transport, which directly 
utilizes chemical, redox or light energy to actively accumu- 
late solutes, and from uniport, which uses neither an ion 
gradient nor other energy source, but allows transport via 
the solute gradient itself [80]. Mitchell assigned the term 
symport o describe solute and ion transport across the 
membrane in the same direction [79]. One of the most 
extensively investigated secondary active transporters i
the E. coli lactose carrier. This review article will focus on 
the molecular biology, biochemistry and physiology of the 
lactose carrier. 
2. General features of the lactose carrier 
2.1. Assays for transport 
A qualitative assay for transport is the fermentation of 
lactose by clones on an indicator plate such as MacConkey 
agar on which lactose positive clones are red. This is a 
convenient screening method for lacY mutants (white 
clones indicate low transport activity). The commonest 
assay for transport of a sugar is to expose cells lacking 
[3-galactosidase to radioactive lactose. The lactose entering 
such cells is not metabolized and is accumulated against a 
lactose concentration gradient (sometimes as high as 200- 
fold). Since thiomethylgalactoside (TMG) is not metabo- 
lized its accumulation may be measured in cells containing 
[3-galactosidase. Another useful assay involves entry of 
lactose into [3-galactosidase-containing cells. In this case 
the lactose is metabolized and the internal concentration f
free lactose remains very low. Thus the entry of lactose is 
thermodynamically 'downhill'. 
The sugar-coupled proton transport is measured in en- 
ergy-depleted cells deprived of oxygen. Sugar is added and 
the pH of the external medium is measured. The rise in 
external pH results from sugar-H + entry into the cells. 
The stoichiometry of the cotransport may be calculated by 
correlating the uptake of radioactive sugar with proton 
entry calculated from the change in pH. 
2.2. Discover3., and demonstration of lactose-proton co- 
transport 
The lactose carrier has become an important general 
model for the study of membrane transport systems. It was 
first described as one of the three structural genes of the 
celebrated lac operon in 1956 by Monod and co-workers 
[94]. Lactose-H + symport (cotransport) across the mem- 
brane was demonstrated from experiments performed by 
West [109] and West and Mitchell [110] who showed 
translocation of H + into energy-depleted E. coli cells 
immediately after addition of lactose. This lactose-H + 
symport process takes place in a 1:1 stoichiometry for 
substrate and ion [111]. Biophysical measurements of the 
size of the carrier (20 ___ 2 ]~) [22], kinetic studies [24], and 
fusion protein studies containing two lactose carrier 
molecules [97] are consistent with the view that the lactose 
carrier functions as a monomer, although this is still a 
matter of controversy. Kinetic analyses of the lactose 
carrier has also provided invaluable information about the 
order of binding, translocation and release of substrate and 
ion ([65,66,87,90,116], and reviewed in Ref. [56] and Ref. 
[89]). However, because it is experimentally difficult to 
measure kinetic parameters for the lactose carrier under 
conditions where both lactose and protons are saturated, 
any mention of K m throughout this article should be 
understood to be the apparent K m rather than the true Kin. 
Although the lactose carrier is probably the best-under- 
stood secondary membrane transport protein, little is known 
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about the precise mechanism of lactose-H + coupling and 
transport. 
2.3. Sequence and structure 
The lactose carrier gene (lacY) was cloned by Teather 
et al. [100] and sequenced by Biichel et al. [16]. lacY was 
predicted to encode a largely hydrophobic 417 amino acid 
polypeptide [27]. Alkaline-phosphatase fusion studies have 
been tremendously useful in the study of the structure of 
the lactose carrier [17]. The current model of the lactose 
carrier shows a polytopic protein with 12 membrane-span- 
ning a-helices [17,27,107], where the N- and C-termini of 
the carrier are present on the cytoplasmic side of the inner 
membrane of E. coli [17,47] (see Fig. 1). With the use of 
an overproducing E. coli strain, Newman et al. [82] puri- 
fied the carrier to homogeneity in functional form. Elec- 
tron microscopy analysis revealed the presence of a cleft in 
the lactose carrier molecule, suggesting a possible site for 
lactose binding [63]. A high resolution three-dimensional 
structure of the lactose cartier has not yet been determined 
nor has one been determined for any symport, antiport or 
uniport protein to date. 
2.4. Expression of two complementary protein fragments of 
the lactose carrier 
Two incomplete fragments of the lactose carrier can 
insert into the cytoplasmic membrane and show a func- 
tional conformation that permits active transport of lactose 
[3,117]. For example, two non-covalently bound segments 
of the lactose carrier, amino acids 1-71 (N2) and amino 
acids 70-417 (C10) placed in a cell showed transport 
activity. In additional experiments of this type, Bibi and 
Kaback [3] showed that, when the lacY gene was split into 
two equal-sized fragments (N6 and C6), the cells express- 
ing both together showed significant transport activity, 
while cells expressing each half alone showed no activity. 
Thus two separate portions of the cartier must associate 
with each other in the membrane in a manner that results 
in function. When the two fragments were expressed indi- 
vidually little protein was found in the membrane but 
when expressed together both N-terminal and C-terminal 
fragments were found in the membrane. Thus the associa- 
tion of the two polypeptides results in a stable and catalyti- 
cally active complex. 
2.5. Deletions in the lactose carrier 
The deletion of the C-terminal 16 amino acids has little 
or no effect on activity. However, deletions of 17, 18, or 
19 amino acids results in 40%, 30% and 25% of normal 
activity respectively [71]. Loss of the C-terminal 20 or 21 
amino acids results in complete loss of activity. Trunca- 
tions of more than 20 amino acids are unstable and are 
proteolyzed at a rapid rate [95]. At the N-terminal end of 
the carrier a deletion of the first 23 amino acids does not 
abolish transport while loss of 38 amino acids results in no 
activity [5,7,76]. 
Bibi et al. [4] have shown that internal deletions of the 
lacY gene which result in the loss of 1 to 6 a-helices fail to 
accumulate lactose. However, the downhill lactose entry 
into [3-galactosidase-containing cellsis still present in such 
deletions if the C-terminal four a-helices are present. 
Presumably there is sugar recognition information in the 
C-terminal 4 helices. 
2.6. The role of phospholipids in lactose transport 
The lactose carrier was partially purified and transport 
activity reconstituted in artificial liposomes by Newman 
and Wilson [83]. This permitted the study of the role of 
different phospholipids in the artificial liposomes on the 
transport activity of the carrier. Maximum accumulation of 
lactose was observed with natural E. coli iipids or mix- 
tures of phosphatidylethanolamine (PE) or phosphatidyl- 
senne (PS) [20,99]. On the other hand, phosphatidylcholine 
(PC) or mixtures of PC and phosphatidylglycerol or cardi- 
olipin showed poor accumulation. Page et al. [88] showed 
that sugar binding was normal in PE-deficient liposomes, 
although accumulation was defective. Bogdanov and 
Dowhan [9] studied lactose transport in an E. coli mutant 
which could not synthesize PE and found that accumula- 
tion of sugar was reduced 5- to 10-fold relative to cells 
containing PE. On the other hand lactose downhill entry 
into 13-galactosidase-containing cells(no accumulation re- 
quired) was normal. Thus carrier-mediated facilitated if- 
fusion was normal while the energy coupling was defec- 
tive. The K m for transport was normal in the cells without 
PE, suggesting that the binding site was normal. The 
localized positive charge at the surface of the membrane 
would repel H + and attract OH making the surface of the 
membrane more alkaline. This could alter the localized 
surface environment for charged residues especially histi- 
dine. How these changes affect transport is not yet under- 
stood. 
3. Evolution of the lactose carrier 
3.1. A superfamily of transporters 
One of the useful techniques in molecular biology is the 
analysis of proteins that share a common evolutionary 
origin. In this regard, the lactose carrier has been postu- 
lated [68] to be a member of a superfamily of related 
transporters independently designated as either the trans- 
porter superfamily (TSF) [37], major facilitator superfam- 
ily (MFS) [68], or most recently, the uniporter, symporter, 
antiporter superfamily (USA) [34]. This superfamily in- 
cludes passive and secondary-active carriers, found in 
organisms ranging from bacteria to humans, which trans- 
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port diverse substrates such as sugars, amino acids, citric 
acid cycle intermediates, antibiotics, and antiseptics [35]. 
Similarities in the structure (12-14 transmembrane do- 
mains) and sequences (conserved amino acids) of these 
functionally-distinct carrier proteins suggest hat the mem- 
bers of this superfamily have a common evolutionary 
origin and thus similar three-dimensional structures, sug- 
gesting that they operate by a common mechanism of 
action [35-37,104,105]. Therefore, findings pertaining to 
one member of the superfamily may be applicable to all 
other members of the superfamily. 
3.2. A family of homologous carriers within the superfam- 
ily 
Carriers that are homologous with the lactose-H + car- 
rier of E. coli include the raffinose-H + carrier (RafB) of 
E. coli [1], the sucrose-H + carrier (CscB) of E. coli [8], 
the lactose-H + carrier (LacY-Kp) of Klebsiella pneumo- 
niae [73], and the lactose-H + carrier (LacY-C0 of Cit- 
robacterfreundii [61]. These carriers are homologous to 
each other and constitute a family within the superfamily 
[34,68]. Fig. 2 shows the multiple amino acid sequence 
alignments of each member of the lactose carrier family. 
3.3. The 'GRR' motif 
Multiple amino acid sequence alignments have revealed 
conserved residues, such as the 'G (X) 3 D R X G R R' 
motif [35,36] in the loop between helices 2 and 3 of all 
members of the superfamily (Figs. 1 and 2). Insertional 
mutagenesis of several contiguous histidine residues into 
the loop 2-3, where the motif resides, resulted in signifi- 
cantly reduced lactose transport, indicating the importance 
of this loop [72]. Recent work has shown that only Asp-68 
of the 'G (X) 3 D R X G R R' motif is critical for full 
activity of the lactose carrier [42]. Surprisingly, earlier 
work on the tetracycline/H + carrier not only showed that 
Asp-66 (corresponding to Asp-68 of the lactose carrier) is 
necessary, but that Gly-62, Gly-69, and Arg-70 of the 
motif were required for function as well [ 119,120]. Perhaps 
an analysis of the 'G (X) 3 D R X G R R' motif in other 
members of the superfamily will be necessary to determine 
if it has a direct functional role in solute transport, and if 
so, what that functional role might be. 
3.4. Other amino acid motif~ 
The lactose carrier also shares some elements of the 'G 
(X) 3 D R X G R R' motif between helices 8 and 9 as well 
as the 'R (X) 3 G (X) 3 G' motif immediately preceding 
helix 4 [36]. Both motifs are found in almost all members 
of the superfamily. The significance of these motifs has yet 
not been evaluated for the lactose carrier. Surprisingly, the 
lactose carrier does not seem to have either the 'P E S P R' 
motif (after helix 6) nor the 'P E T K' motif (after helix 
12), both of which have primarily been found in sym- 
porters and uniporters of the superfamily [36]. 
4. The history of mutagenesis of the lactose carrier 
Extensive mutagenesis of the lacY gene (over 500 
mutants) was first reported by Hobson et al. [39]. One 
interesting set of 179 mutants failed to grow on 5 mM 
lactose but grew on 100 mM lactose. These 'leaky' or 
'Km' mutants were located primarily in the second half of 
the lacY gene. Two of these K m mutants were later 
cloned and sequenced revealing His-322--*Yyr [49,51] 
and Asp-237--* Asn [55]. Additional discussion of other 
mutations of these two amino acids follows later on in this 
article. 
Some of the early studies of the structure-function 
relationships of the lactose transport protein focused atten- 
tion on the cysteine residues. Kennedy and co-workers [28] 
first observed that N-ethylmaliemide (NEM), a 
sulfhydryl-specific reagent, inhibited lactose carrier activ- 
ity and that the inhibition was greatly reduced by the 
addition of thiodigalactoside (a high affinity substrate of 
the carrier). This suggested that one or more Cys residues 
somehow dictated the substrate-binding site of the lactose 
carrier. It was later shown by site-directed mutagenesis 
that Cys-148 was the amino acid protected by substrate 
against he inhibitory effects of NEM [2,44,118]. However, 
since the mutant Cys-148 ~ Ser was active, Cys-148 itself 
was not critical for full activity of the carrier [81,98]. 
Eventually, the remaining Cys residues were individually 
changed to serine and each found to be active 
[12,74,75,81,98,101,103,106]. When all of the 6 cysteines 
in membrane spanning helices were changed to serine, the 
cysteine-less carrier showed 60% normal activity [103]. 
Starting with the Cys-less carrier, residues of a particular 
helix (or region) of the carrier were individually replaced 
by a Cys residue. To date, cysteine-scanning mutagenesis 
has been performed on helices 1, 3, 5, 7, 9, 10 and 11 of 
the carrier [47,108]. It was concluded from these studies 
that only relatively few residues were essential for activity 
(see below). 
Further, lactose accumulation was severely defective 
when several residues in helix 8 were replaced by other 
amino acids [38]. Using amber suppressor analysis, in 
which as many as 12 amino acids can be placed into the 
position of a single stop codon, Huang et al. showed that 
substitutions for Trp-10, Gln-219, Gln-256, and Gln-379 
had modest-to-good transport activity [41]. However, Trp- 
33 changed to Pro drastically reduced lactose carrier func- 
tion while Lys, Leu, Cys or Glu mutant moderately re- 
duced lactose carrier function [41]. Other replacements for 
Trp-33 resulted in changes in sugar specificity where, for 
instance, Ser, Gln, Tyr, Ala, Gly or Phe mutants increased 
the rate of transport for the lactose analog methyl-[3-D-thio- 
galactopyranoside (TMG). Fig. 1 illustrates the locations 
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Fig. I. Mutations in the lactose carrier of E. coll. Amino acid residues in dark squares with white lettering indicate that replacements at this position result in less than 25% normal actose accumulation. 
Circled residues have been replaced by several other amino acids. One or more substitutions were inactive (less than 25% of normal), while others were more active (between 25-100% of normal). Residues 
in white squares represent mutations that were moderately active (25-50% of normal). Residues shown in red are those in which mutations resulted in greater than 50'~/,~ activity. The remaining residues 
(black) have not been mutated. 
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and effects of specific mutations on active lactose accumu- 
lation in a two-dimensional model of the lactose carrier. 
Kaback's laboratory has examined all or most of the 
glycines, serines, prolines, histidines, tryptophans, and ty- 
rosines (last reviewed in Ref. [47]). Taken together with 
many other mutants, the lactose carrier is probably the 
Hel ix  1~ 
LacY-Cf  MYYLK NTNFWMFGFF FFFYFF IMGA YFPFFP IWLH EVNHISKGDT 
LacY-Ec  MYYLK NTNFWMFGLF FFFYFF IMGA YFPFFP IWLH DINHISKSDT 
LacY-Kp  MKLSELAPRE RHNFIYFMLF  FFFYYF IMSA YFPFFPVWLA EVNHLTKTET 
RafB  MNSASTHK NTDFWIFGLF  FFLYFF IMAT CFPFLPVWLS DWGLSKTDT 
CscB MALNIPFR NAYYRFASSY SFLFF ISWSL WWSLYAIWLK GHLGLTGTEL  
Consensus  . . . . . . . . . . . . . . . . . . . . .  F . . . . . . . . . . . . . . .  WL  . . . . . . . . . . .  
= . . . . . . .  He l ix  2 He l ix  3 . . . . . .  
LacY-Cf  G I IFACISLF  SLLFQPIFGL  LSDKLGLRKH LLWVITGMLV MFAPFF IYVF  
LacY-Ec  G I IFAA ISLF  SLLFQPLFGL LSDKLGLRKY LLWI ITGMLV MFAPFF IF IF  
LacY-Kp  G IVFSCISLF  A I IFQPVFGL ISDKLGLRKH LLWTIT ILL I  LFAPFF IFVF  
RafB  G IVFSCLSLF  A ISFQPLLGV ISDRLGLKKN L IWSISLLLV FFAPFFLYVF  
CscB GTLYSVNQFT S ILFMMFYGI  VQDKLGLKKP L IWCMSFILV  LTGPFMIYVY 
Consensus  G . . . . . . . . . . . .  F . . . .  G -  - -D-LGL-K -  L -W . . . . .  L . . . .  PF  . . . . .  
==-----=--=====Helix 4 
LacY-Cf  GPLLQVNILL  GS IVGGIYLG F IYNAGAPAI  EAY IEKASRR SNFEFGRARM 
LacY-Ec  GPLLQYNILV  GS IVGGIYLG FCFNAGAPAV EAF IEKVSRR SNFEFGRARM 
LacY-Kp  SPLLQMNIMA GALVGGVYLG IVFSSRSGAV EAY IERVSRA NRFEYGKVRV 
RafB  APLLHLNIWA GALTGGVFIG FVFSAGAGAI  EAY IERVSRS SGFEYGKARM 
CscB EPLLQSNFSV GL ILGALFFG LGYLAGCGLL  DSFTEKMARN FHFEYGTARA 
Consensus  -PLL - -N- - -  G - - -G  . . . .  G . . . . . . . . . . . . . .  E - - -R -  - -FE -G- -R -  
=====Hel ix  5 . . . . . . .  ====--=-==Hel ix 6 
LacY-Cf  FGCVGWALCA S IAGIMFT IN  NQFVFWLGSG CAVILALLLL  FSKTDVPSSA 
LacY-Ec  FGCVGWALCA S IVGIMFT IN  NQFVFWLGSG CAL ILAVLLF  FAKTDAPSSA 
LacY-Kp  SGCVGWALCA S ITGILFS ID  PNITFWIASG FAL ILGVLLW VSKPESSNSA 
RafB  FGCLGWALCA TMAGILFNVD PSLVFWMGSG GALLLLLLLY  LARPSTSQTA 
CscB WGSFGYAIGA FFAGIFFS IS  PH INFWLVSL  FGAVF.MMIN MRFKDKDHQC 
Consensus  -G- -G-A- -A  - - -G I -F  . . . . . . .  FW- -S  . . . . . . . . . . . . . . . . . . . . .  
:Hel ix  7 . . . . . .  
LacY-Cf  KVADAVGANN SAFSLKLALE LFKQPKLWLI  SLYVVGVSCT YDVFDQQ.FA 
LacY-Ec  TVANAVGANH SAFSLKLALE LFRQPKLWFL SLYV IGVSCT YDVFDQQ.FA 
LacY-Kp  EV IDALGANR QAFSMRTAAE LFRMPRFWGF I IYVVGVASV YDVFDQQ.FA 
RafB  MVMNALGANS SL ISTRMVFS LFRMRQMWMF VLYT IGVACV YDVFDQQ.FA 
CscB IAADAGGVKK EDF . . . . .  IA  VFKDRNFWVF V IF IVGTWSF YNIFDQQLFP  
Consensus  . . . .  A -G  . . . . . . . . . . . . . .  F . . . . .  W . . . . . . .  G . . . .  Y- -FDQQ-F -  
=== He l ix  8 ==== 
LacY-Cf  NFFTSFFATG EQGTRVFGYV TTMGELLNAS IMFFAPL IVN R IGGKNALLL  
LacY-Ec  NFFTSFFATG EQGTRVFGYV TTMGELLNAS IMFFAPL I IN  R IGGKNALLL  
LacY-Kp  NFFKGFFSSP QRGTEVFGFV TTGGELLNAL IMFCAPAI IN  R IGAKNALL I  
Ra fB  IFFRSFFDTP QAGIKAFGFA TTAGEICNAI  IMFCTPWI IN  R IGAKNTLLV 
CscB VFYAGLFESH DVGTRLYGYL  NSFQWLEAL CMAI IPFFVN RVGPKNALL I  
Consensus  -F  . . . .  F . . . . .  G . . . .  G . . . . . . . . . .  A -  -M- - -P - - -N  R -G-KN-LL -  
==== • He l lx  9====== =======Hel ix  I0===== 
LacY-Cf  AGT IMSVRI I  GSHSHT.ALE  VV ILKTLHMF E IPFL IVGCF KY ITSQFEVR 
LacY-Ec  AGTIMSVRI I  GSSFATSALE VV ILKTLHMF EVPFLLVGCF KY ITSQFEVR 
LacY-Kp  AGL IMSVRIL  GSSFATSAVE V I I LKMLHMF E IPFLLVGTF KY ISSAFKGK 
RafB  AGGIMTIR IT  GSAFATTMTE WILKMLHAL EVPFLLVGAF KY ITGVFDTR 
CscB GVVIMALRIL  SCALFVNPWI  ISLVKLLHAI  EVPLCVISVF  KYSVANFDKR 
Consensus  - - - IM- -R I  . . . . . . . . . . . . . . .  K -LH- -  
. . . . . .  ~Hel ix  11: . . . . . . .  
LacY-Cf  FSAT IYLVCF CFFKQLAMIF  MSVLAGKMYE 
LacY-Ec  FSAT IYLVCF CFFKQLAMIF  MSVLAGNMYE 
LacY-Kp  LSATLFL IGF  NLSKQLSSW LSAWVGRMYD 
RafB  LSATVYL IGF  QFSKQLAAIL  LSTFAGHLYD 
CscB LSST IFL IGF  Q IASSLGIVL  LSTPTGILFD 
Consensus  -S -T - -L - -F  . . . . .  L . . . . .  S - - -G  . . . .  
E-P  . . . . . .  F KY  . . . .  F - - -  
. . . .  He l ix  12=== 
SIGFQGAYLV LGI IRVSFTL  
S IGFQGAYLV LGLVALGFTL  
TVGFHQAYL I  LGCITLSFTV 
RMGFQNTYFV LGMIVLTVTV 
HAGYQTVFFA ISGIVCLMLL  
- -G  . . . . . . . . . . . . . . . . .  
45 
95 
145 
195 
244 
294 
344 
394 
LacY-Cf  ISVFTLSGPG PFSLLRRRES VAL  
LacY-Ec  ISVFTLSGPG PLSLLRRQVN EVA 417 
LacY-Kp  ISLFTLKGSK TLLPATA 
RafB  ISAFTLSSSP G IVHPSVEKA PVAHSEIN  
CscB FGIFFLSKKR EQIVMETPVP SAI  
Consensus  - - -F -L  . . . . . . . . . . . . . . . . . . . . . .  
Fig. 2. Multiple amino acid sequence alignment. This alignment was generated by the Genetics Computer Group PILEUP computer program according to 
the parameters used in Refs. [35] and [104]. The locations of transmembrane domains are denoted as a double-line above the alignments. Amino acids that 
are conserved in all members of this family are shown in the consensus line. LacY-Cf, the lactose-H + carrier of Citrobacterfreundii [61]; LacY-Ec, the 
lactose-H + carrier of E. coli [16]; LacY-Kp, the lactose-H + carrier of Klebsiella pneumoniae [73]; RafB, the raffinose-H + carrier of E. coli [1]; CscB, the 
sucrose-H + carrier of E. coli [8]. The numbers refer to the residues of the LacY-Ec sequence. This figure was provided courtesy of Dr. Jeffrey K. Griffith 
of the University of New Mexico, School of Medicine. 
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most mutagenized transport protein ever examined. Sur- 
prisingly, only about a dozen or so of the amino acids in 
the lactose carrier were found to be absolutely essential for 
lactose cartier function, while about he same number were 
shown to be moderately important. Of these critical residues 
many of them reside within transmembrane domains (Fig. 
1) and about half of the critical residues are conserved in 
members of the family that includes the lactose carrier 
(Fig. 2 [34]). 
5. The role of His-322 
Substitution of His-322 by Arg, Asn, Gln or Lys re- 
sulted in a carrier with defective lactose accumulation and 
proton translocation, but normal downhill lactose transport 
[86,91]. Additional work indicated the importance of Glu- 
325 and Arg-302 for the activity of the lactose carrier (see 
Kaback et al. [47] for a review). On the basis of these and 
other experiments, Kaback [46] proposed that H ÷ is 
translocated through the carrier by protonation and depro- 
tonation of residues Arg-302, His-322 and Glu-325 in a 
manner similar to the charge-relay mechanism found in 
chymotrypsin [6]. 
Cloning and sequencing of a mutant with poor apparent 
affinity for lactose revealed that His-322 was changed to 
Tyr [49,54]. Site-directed mutagenesis of His-322 to Phe or 
Tyr showed poor downhill entry at low sugar concentra- 
tion but good entry at 30 mM concentrations (red on 
MacConkey plates) [50]. No accumulation of lactose and 
melibiose was observed, whereas proton uptake was de- 
tected in both Phe-322 and Tyr-322 mutants. Although 
sugar accumulation and downhill transport were signifi- 
cantly reduced for the His-322 ~ Asn mutant, it showed a 
normal actose:H + stoichiometry [30]. One possible expla- 
nation consistent with these data is that the mutant carrier 
has a very much reduced affinity for lactose. Brooker thus 
concluded that an ionizable histidine residue at 322 is not 
absolutely essential for proton translocation. Although these 
studies are consistent with the notion that His-322 may not 
be required for proton uptake, it is clear that His-322 is 
essential for substrate selection, binding or transport (see 
below). 
6. Sugar recognition mutants of the lactose carrier 
In studies designed to delineate amino acid residues that 
are important for sugar selection or recognition, in 1985 
Brooker and Wilson found lactose carrier mutants with an 
increased capacity to transport the disaccharide maltose by 
incubating E. coli cells containing a plasmid encoding a 
normal actose carrier on minimal plates with maltose and 
selecting for mutants that grew better than normal [10]. 
DNA sequencing of these maltose-specific mutants re- 
vealed mutations at two sites for the lactose carrier: Ala-177 
Table 1 
Sugar-recognition mutants of the lactose carrier 
Sugar(s) used Cell used Mutants Ref. 
for selection for selection 
Sucrose normal A 177V [52] 
Arabinose normal A177V, I, L, F or P [33] 
Maltose normal A 177V or T [ 10,69] 
normal Y236F, N, S, or H 
normal T266I 
Maltose plus normal Y236F [21] 
Cellobiose normal $306T 
normal A386P 
V177 AI77V/Y236F or N 
V177 AI77V/S306T or L 
V177 A177V/K319N 
V177 A177V/H322Y, N or Q 
Maltose normal Y236H, F, or N [26,29] 
plus TDG V 177 A 177V/Y236H 
V 177 A177V/I303F 
V 177 A 177V/H322N 
T306 S306T/Y236F or H 
V177/T306 A 177V/S306T/Y236N 
Maltotriose V177 A177V/F236H or N [84] 
V 177 A 177V/S306T 
V 177 A 177V/H322N 
H236 Y236H/S306T 
VI77/N236 A177V/Y236N/S306T 
changed to Val or Thr, and Tyr-236 changed to Phe, Asn, 
Ser or His (see Table 1). All mutants showed higher 
maltose transport rates than normal [10], and a normal 
[3-galactoside:H ÷ stoichiometry [11]. When cells were se- 
lected for growth on sucrose a cell was isolated with the 
Ala-177 ~ Val mutation [52]. The Val-177 mutation con- 
fers an enhanced transport for sucrose as well as the 
maltose analog 4-nitrophenyl-ot-maltoside [52]. Therefore, 
the Val-177 mutation was more closely studied [53]. E. 
coli containing this particular mutant achieved downhill 
transport, but not accumulation, of sucrose. A kinetic 
analysis of Val-177 showed that the Vma x values for both 
melibiose and TMG were decreased [53]. The K m for 
melibiose was increased, whereas the K m for TMG was 
decreased. Interestingly, the K m value for the lactose 
analog 2-nitrophenyl-13-D-galactopyranoside (13-ONPG) 
was unchanged, whereas the Vma x was increased several- 
fold. Various sugars [maltose, cellobiose (glucose 13-1,4- 
glucoside) and palatinose (glucose ~x-1,6-fructofuranoside)] 
were able to block [3-ONPG transport in the Val-177 
mutant, but not in the wild-type. Markgraf et al. showed 
that Thr-266 ~ Ile of the lactose carrier substantially re- 
duced lactose transport, but enhanced maltose transport 
[69]. Goswitz and Brooker later observed that mutants 
which grew well on minimal plates containing arabinose 
also turned out to be Ala-177 changed to Val [33]. Mutants 
in which Ala-177 was changed to Ile, Leu, Phe or Pro, by 
site-directed mutagenesis recognized arabinose. Taken to- 
gether, these various data (Table 1) clearly demonstrate 
that Ala-177, Tyr-236 and Thr-266 mediate sugar selection 
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properties of the lactose carrier, possibly through modula- 
tion of either the Vm, × or kcat /K  m ratio of the carrier. 
Another type of sugar recognition mutant was isolated 
by selection on maltose minimal plates containing cel- 
lobiose, which inhibits maltose transport [21]. Sequencing 
of the plasmid DNA derived from E. coli  cells selected by 
the above procedure showed three types of mutants: Tyr- 
236 --* Phe, Ser-306 --* Thr, or Ala-386 --* Pro. Sequencing 
of DNA derived from the Val- 177 mutants, which grew on 
maltose-cellobiose minimal plates, revealed the original 
Val-177 mutation plus the following second-site mutants 
(Table 1): Tyr-236 ~ Phe or Ash, Ser-306 --* Thr or Leu, 
Lys-319 ~ Asn or His-322 ~ Tyr, Asn or Gln. The Val- 
177/Asn-319 double mutant was able transport various 
sugars without protons as well as mediate a proton leak 
under conditions of an electrochemical gradient of protons 
[14]. Third-site revertants of the double mutant were iso- 
lated in which cells were able to recognize maltose and 
were resistant to TDG inhibition of growth [26]. In another 
experiment, normal cells and maltose-positive mutants were 
plated on maltose plus TDG (a potent inhibitor of the 
lactose carrier) [29]. Sequencing of the mutants that grew 
well under these conditions revealed changes occurring at 
Tyr-236, I1e-303 or His-322 (see Table I). Two types of 
revertants were found that retained the original double 
mutations plus a new mutation at a third site: Ile-303 
changed to Phe and Tyr-236 changed to Ash or His. These 
triple mutants were similar in that each showed some 
lactose downhill transport, but very little lactose accumula- 
tion. Olsen et al. showed that two or three mutations 
within the same lactose carrier molecule conferred the 
ability to recognize the trisaccharide maltotriose [84]. The 
mutations occurred at Ala-177, Tyr-236, Ser-306 or His- 
322. In brief, these results, summarized in Table 1, sug- 
gested that all or some of these amino acids (Ala-177, 
Tyr-236, Ile-303, Ser-306, Lys-319, His-322, and Ala-386) 
either line the aqueous-facing binding site [77] (see Fig. 3), 
or that these amino acids form supporting structures for the 
actual sugar-binding site. 
7. Energy coupling and uncoupling in the lactose car- 
rier 
7.1. Mutants  that transport  sugars without protons  
The coupling of proton transport to lactose transport is 
essential for the process of sugar accumulation. Several 
mutants have been isolated in which this coupling is 
defective and various types of energy uncoupled pheno- 
types have been observed. In 1970, Wong et al. [115] 
isolated an E. coli  mutant which failed to accumulate 
thiomethylgalactoside (TMG) or the lactose analog o- 
nitrophenyl-[3-galactoside (ONPG) but showed normal 
downhill lactose entry and downhill ONPG entry 400% of 
normal [115]. West and Wilson showed that this mutant 
~~ NH3+ 
Fig. 3. Residues involved in sugar ecognition. Hypothetical three-dimen- 
sional model of the lactose carrier indicating the position of residues 
involved in sugar ecognition (from Matos et al. [70] and adapted from 
Collins et al. [21]). 
was unable to translocate protons across the membrane 
after the addition of TMG [112]. This was the first demon- 
stration of a mutant with a defect in the coupling between 
cation entry and sugar accumulation i a carrier protein. In 
essence, the lactose carrier was converted from a sym- 
porter into a uniporter. The cloning and sequencing of this 
uncoupled mutant revealed that Gly-159 was changed to 
Cys [70]. The mutant showed an increased sensitivity to 
several sulfhydryl reagents, including NEM, which is con- 
sistent with the view that Gly-159 is in or near the sugar 
recognition site (see Fig. 3) and the energy coupling region 
of the carrier. It is not yet known whether substrate 
protects the Cys-159 mutant from the effects of NEM. 
Another energy-uncoupled mutant was isolated in 1973, 
which showed defective thiomethylgalactoside accumula- 
tion, but maintained an ability to mediate thiogalactoside 
downhill transport [57,114]. The ONPG downhill transport 
rate of the mutant was twice that of the parent. Cloning 
and sequencing of the lacY in this mutant found that 
Gly-262 was replaced by Cys [13]. Under conditions where 
both the mutant and normal carriers transport lactose 
downhill at comparable rates, no sugar-induced proton 
translocation was detected in the mutant. Furthermore, the 
mutant carrier was more sensitive to the sulfhydryl reagents 
than the wild-type carrier and was protected by substrate 
against their inhibitory effects. This indicated that, like 
Gly-159, Gly-262 also played a role in energy-coupling 
and affected the substrate-binding site. Changing many 
charged residues to neutral amino acids results in the loss 
of lactose accumulation while downhill entry of lactose 
remains intact. For example, Piittner et al. demonstrated 
that His-322 changed to Asn or Gln showed complete loss 
of lactose accumulation, but were positive on indicator 
plates [93]. 
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7.2. Mutants that transport protons without sugars 
A second type of uncoupled mutant transports protons 
in the absence of sugar [53]. When expression of the 
carrier was induced, proton transport (or 'leak') caused a 
severe inhibition of cell growth by reducing the proton- 
motive force generated by the respiratory chain. These 
proton-leaky mutants had been isolated as maltose-positive 
[10] and sucrose-positive [52] mutants where Ala-177 was 
changed to Val and Tyr-236 was changed to His, Asn, Phe 
or Ser. The Val-177 mutant showed a lower than normal 
protonmotive force and a higher than normal rate of proton 
entry into the cells [53]. Brooker showed that the double 
mutant Val-177/Asn-319 was able to transport protons 
without sugar [14,15]. 
7.3. Mutants that ' leak' protons in the presence o f  sugar 
Brooker [ 15] discovered an unusual proton leak mecha- 
nism which he designated as the leak B pathway (the leak 
A pathway was proton leak in the absence of sugar). He 
found that sugars inhibited the growth of A177V/K319N 
on rich plates (complete inhibition with 0.5 mM TDG and 
partial inhibition with 2.5 mM TMG or 2.5 mM lactose). 
In the presence of the sugar there is an abnormally rapid 
leak of protons which reduces the protonmotive force and 
Table 2 
Properties of mutants of charged residues 
Mutant Accumulation (% normal) Downhill (% normal) 
lactose TMG melibiose lactose 
Fermentation (MacConkey) Expression (% normal) Ref. 
melibiose 
D237N 0 0 0 
K358T 0 3 0 
K358T/D237Y 5 25 45 
K358T/D237N 30 80 85 
K358T/D237G 60 95 84 
D237N/K358Q 50 42 83 
D237C 5 
D237A 0 
D237K 0 
K358C 0 
K358A 0 
K358D 0 
D237C/K358C 75 
D237C/K358A 75 
D237A/K358C 70 
D237K/K358D 60 
D240A 5 0 15 
D240A/K319Q 20 10 35 
K319N 0 0 0 
K319N/D240V 40 30 25 
K319N/D240G 25 20 15 
K319L 0 0 0 
K319L/D240A 30 0 0 
K319L/D240Y 30 0 25 
E269Q 0 0 0 
E269Q/K319N 0 0 0 
D240C 0 
D240A 0 
K319C 0 
D240C/K319C 25 
D240C/K319A 33 
D240A/KK319C 33 
D240A/K319A 35 
D240K 0 
K319D 0 
D240K/K319D 0 
E325S 0 0 0 
H322D 2 2 1 
E325S/H322N 0 0 3 
E325S/H322D 0 0 2 
H322N 0 0 3 
E325N 0 0 0 
H322N/E325N 0 0 0 
30 
30 
25 
100 
80 
10 
75 
45 
0 
0 
5 
1 
0 
2 
25 
1 
38 
white 
white 
red 
red 
red 
red 
white 
red 
white 
red 
red 
white 
red 
red 
white 
red 
white 
white 
red 
red 
red 
white 
red 
25 
40 
15 
5 
5 
40 
15 
15 
15 
50 
94 
83 
83 
40 
48 
43 
74 
84 
100 
100 
100 
100 
100 
100 
100 
47 
101 
36 
119 
95 
68 
7O 
[55] 
[55] 
[55] 
[55] 
[55] 
[55] 
[25] 
[25] 
[25] 
[25] 
[25] 
[25] 
[25] 
[25] 
[251 
[251 
[59] 
[59] 
[60] 
[60] 
[60] 
[60] 
[60] 
[60] 
[60] 
[6o] 
[96] 
[96] 
[96] 
[96] 
[96] 
[96] 
[96] 
[96] 
[96] 
[96] 
[62] 
[62] 
[62] 
[62] 
[62] 
[62] 
[62] 
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inhibits growth. The explanation for the phenomenon ap- 
pears to be influx of sugar together with protons and 
subsequent effiux of sugar without protons [26,59]. A 
kinetic model has been proposed to explain the behavior of 
various uncoupled mutants of the lactose carrier in which 
two leak pathways involving a reorientation of either the 
proton binding site (a proton leak) or the substrate binding 
site (a substrate leak) [67]. This model is consistent with 
earlier work suggesting that in the normal carrier, two 
conformations exist: one with the binding site open to the 
cytoplasm of the cell while closed to the periplasm and the 
opposite situation in which the binding site is open to the 
periplasm but closed to the cytoplasm [23,85]. 
8. Charged amino acids and salt-bridges 
It is striking that some of the charged amino acids in the 
lactose carrier are highly conserved throughout evolution, 
are important for substrate selectivity and play a role in 
energy transduction. The presence of charged amino acid 
residues within a transmembrane r gion of a carrier is 
thermodynamically unfavorable unless they face the aque- 
ous environment or are neutralized by another esidue with 
the opposite charge. 
8.1. The Asp-237-Lys-358 salt bridge 
In 1991, King and Wilson studied two mutants in which 
a charged amino acid was changed to a neutral residue 
(Lys-358--* Thr and Asp-237--* Asn) [55]. Each mutant 
showed a severe defect in the accumulation of lactose, 
melibiose and TMG (Table 2). The Lys-358 --* Thr mutant 
displayed no lactose or melibiose downhill entry as judged 
by white colonies on melibiose MacConkey plates and by 
the sugar transport assay [55]. After several days incuba- 
tion at 37°C on melibiose MacConkey plates, red rever- 
tants of Thr-358 were isolated. Revertants from the Asn- 
237 were isolated by growth on melibiose minimal medium. 
All revertants of Lys-358 ~ Thr contained the original 
Thr-358 mutation plus a second mutation at Asp-237 
which was changed to a neutral amino acid (Ash, Gly or 
Tyr). Revertants from the Asn-237 mutant were isolated in 
the same manner. These revertants retained the original 
Asn-237 mutation plus Lys-358 changed to Gin. All of the 
second-site revertants howed sugar transport better than 
the starting single mutation but less than normal (Table 2). 
Because both types of revertants resulted in the neutraliza- 
tion of an amino acid of opposite charge, it was reasonable 
to conclude that Asp-237 and Lys-358 were in locations 
close enough in the three-dimensional space of the carrier 
that a salt-bridge could form between both residues (see 
Fig. 4.) [55]. Dunten et al. showed that replacement of 
either residue with Cys showed severe defects in transport, 
whereas the double mutant Cys-237/Cys-358 showed 75% 
of normal transport [25]. When a mutant was constructed 
Fig. 4. Postulated salt-bridges within the lactose carrier of E. coli. 
where both charges were reversed (Lys-237/Asp-358), 
good transport activity was observed by Sahin-Toth et al. 
[96]. Consequently, although each amino acid of the salt- 
bridge is required for full activity, neither the salt-bridge 
per se nor the orientation of the charges are essential for 
lactose transport [25]. Sahin-Toth et al. [96] have suggested 
that the salt-bridge formed by Asp-237 and Lys-358 is 
necessary for stability or insertion of the lactose carrier in 
the membrane. 
8.2. The Asp-240-Lys-319 salt bridge 
Replacement of Asp-240 with an Ala residue in the 
lactose carrier diminished its ability to accumulate meli- 
biose, lactose and TMG [59]. A fast-growing revertant of 
the Ala-240 mutant was isolated on melibiose minimal 
plates. The primary mutation was present plus Lys-319 
was changed to Gln. The revertant showed better accumu- 
lation than either Ala-240 or Gln-319 (Table 2). The 
Ala-240/Gln-319 revertant strongly suggested that Asp- 
240 and Lys-319 interact and probably form a salt-bridge 
(Fig. 4). When the charges of Asp-240 and Lys-319 were 
reversed transport activity was poor [96], which is consis- 
tent with the notion that the positions of the residues in 
this salt-bridge are functionally important. 
8.3. The Lys-319-Asp-240 and Lys-319-Glu-269 salt 
bridges 
Converting Lys-319 to Asn resulted in the inability of 
the host cell to ferment melibiose on MacConkey plates 
[60]. Second-site suppressor analysis of this mutant re- 
vealed the original mutation (Asn-319) plus mutations at 
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GLU269 LYS319 
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ASP240 
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B. 
H ÷ 
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(D 
Fig. 5. Proposed mechanism for sugar-proton symport. (A) The sugar in 
the binding pocket of the carrier with the salt-bridge (between Glu-269 
and Lys-319) preventing sugar transport. Protons are drawn into the 
pocket by an inwardly directed proton motive force. (B) The protonation 
of Glu-269 with opening of the gate. Asp-240 facilitates this process by 
attracting Lys-319 and forming a salt-bridge. The sugar then passes 
through the membrane into the cytoplasm. (C) The loss of the proton 
from Glu-269 and re-establishment of the original salt-bridge with Lys- 
319. Adapted from Lee et al. [60]. 
one of two separate sites: Asp-240 changed to Val or Gly 
and Glu-269 changed to Asn. Likewise, conversion of 
Lys-319 to Leu failed to ferment melibiose on MacConkey 
plates. Revertants of this primary mutant proved to have 
second-site mutations at Asp-240 (Ala or Tyr). These two 
revertants showed greater transport than the original Leu- 
319 mutant. In a second series of experiments, revertants 
were isolated from the primary mutant Glu-269--* Ash, 
which grew poorly on melibiose minimal plates. The meli- 
biose-positive revertants included the double mutant Gln- 
269/Asn-319. Together, these data strongly suggested that 
Lys-319 forms a salt-bridge with both Asp-240 and Glu-269 
(Fig. 4). Since all the revertants i olated from mutants for 
Glu-269 were severely defective with respect to their 
ability to accumulate sugars, the salt-bridge between Glu- 
269 and Lys-319 could be more critical for the function of 
the carrier than the salt-bridge between Asp-240 and Lys- 
319. This finding led to the formulation of a hypothetical 
mechanism, illustrated in Fig. 5, in which binding of the 
proton to Glu-269 neutralizes it, thus setting free the 
Lys-319 which then binds to Asp-240. This opens the 
channel and allows sugar to pass across the membrane. 
8.4. The His-322-Glu-325 salt bridge 
Substantial evidence has accumulated demonstrating the 
functional importance of His-322 and Glu-325 in sugar 
transport [ 18,19,30,31,49-51,58,86,91-93]. Carisco et al. 
suggested that Glu-325 and His-322 were ion-paired be- 
cause both amino acids are only three residues apart in the 
primary sequence and are believed to reside in an a-helical 
region of the carrier [18]. Jung et al. [43] converted both 
charged residues to cysteines and added a fluorescent 
reagent (pyrene-maleimide). This exhibited excimer fluo- 
rescence, indicating that the two residues were within 
about 3.5 .A of each other. This result would be expected if
the two residues were in an a-helical region. A physio- 
logical approach to this question was carried out with the 
initial mutant Glu-325--* Ser, which failed to ferment 
melibiose (white clones on MacConkey indicator plates) 
[31,62]. A red revertant was isolated which showed a 
second site mutation at His-322 (Glu-325 --* Ser/His-322 
--* Asn) [62]. This suggested that His-322 and Glu-325 
interact to form a salt-bridge (Fig. 4). In an additional 
experiment the double mutant His-322 --* Asn/Glu-325 --* 
Asn was constructed by site-directed mutagenesis. This 
double mutant showed a greater gma x for lactose transport 
than either of the single mutants His-322 ~ Asn or Glu- 
325 --* Asn (Table 2). These results also provided physio- 
logical evidence to support he view that His-322 interacts 
with Glu-325. 
The postulated role of Glu-325 in proton transport 
[18,31] is supported by the fact that a second-site r vertant 
of Ser-325 (Ser-325/Asp-322), which contains a negative 
charge substituted for His-322, is capable of sugar-proton 
cotransport [62]. Although sugar accumulation does not 
take place, melibiose-stimulated proton uptake is present 
(30% of normal). Remarkably, the Ser-325/Asp-322 re- 
vertant shows very high TDG-stimulated proton uptake. 
Hence, this double mutant demonstrates that a carboxyl 
group substituted for His-322 can compensate for the loss 
of the carboxyl group at the 325 position in proton cotrans- 
port. It is interesting to note that a negative charge in this 
region is more important han an intact His-322. These 
experiments emphasize the importance of Glu-325 in the 
physiology of sugar transport, probably in proton binding 
and transport. 
Site-directed pyrene excimer fluorescence studies [43] 
and EPR spectroscopy [45] suggest that His-322 is close to 
Glu-269. Thus, His-322 may salt bridge with Glu-269. A 
second example of a positive residue interacting with two 
different negative residues is the case of Lys-319 interact- 
ing with both Glu-269 and Asp-240 [60]. We postulate that 
at one phase of the transport cycle Lys-319 interacts with 
Glu-269 [60] and His-322 interacts with Glu-325 [62]; at 
another phase of the cycle His-322 interacts with Glu-269, 
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Glu-325 interacts with Arg-302 [43,45], and Lys-319 inter- 
acts with Asp-240 [59,60]. Such alterations in salt bridges 
may be involved in the conformational changes that occur 
during the transport cycle. 
If His-322 (or other important residue) were one of the 
elements of the sugar binding site, one would expect that 
mutation of this amino acid would significantly reduce 
transport but not necessarily abolish function. The lactose 
binding site of S-lac Lectin has been studied by analysis of 
X-ray crystal structure and nine specific interactions 
(mostly hydrogen bonds) are known to occur between the 
sugar and specific amino acid residues in the protein 
structure [64]. One might predict that altering one of the 
amino acids in the binding site would reduce the affinity of 
the protein for the sugar but the remaining eight interac- 
tions would permit partial binding affinity. Similarly loss 
of one amino acid residue in the lactose binding site of the 
lactose carrier would be expected to reduce but not abolish 
binding of the sugar. 
9. Nature of the lactose carrier sugar- and cation-bind- 
ing site(s) 
9.1. A binding site for lactose 
The exact three-dimensional structure of the lactose 
binding site in the lactose carrier is unknown although 
several amino acid residues indicated above are presumed 
to be in or near this binding site. Recently X-ray crystallo- 
graphic data for the lactose binding site of the human S-lac 
lectin was published [64]. Residues that form hydrogen 
bonds with the lactose include a lysine, histidine, glutamic 
acid, two arginines and two asparagines. We speculate that 
the binding site of the lactose carrier may be similar to that 
found in this lectin. Fig. 6 shows the proposed hydrogen 
bonds between the amino acid residues in the binding site 
of the lactose carrier and the various hydroxyls of the 
lactose molecule. Shown for comparison is the structure 
found in the lectin. The charged residues of the lactose 
carrier given in the figure are among those known to be 
important for sugar recognition from physiological studies 
discussed above. His-322, for example, when changed to 
Phe, Tyr or Ash, results in altered sugar ecognition [51,30]. 
Likewise, mutants of Lys-319 show altered sugar recogni- 
tion [60]. It is interesting to note that two key residues in 
the lectin binding site include a histidine (His-45) and an 
arginine (Arg-49) which are 4 residues apart and in the 
proposed structure in the lactose carrier binding-site the 
histidine (His-322) is three residues away from the lysine 
(Lys-319). We propose (Fig. 4) that in the absence of 
sugar the charged residues are salt-bridged [His-322 to 
Glu-325 (and Glu-269), Lys-319 to Asp-240 (and Glu-269) 
and Arg-302 to Glu-235]. Thus the charged residues essen- 
tial for sugar binding can be stabilized in the hydrophobic 
environment of the empty carrier by salt-bridging. X-ray 
crystallographic structure of the lac repressor (lacR) bound 
to isopropylthiogalactoside (IPTG) has recently been pub- 
lished [32]. Hydrogen bonding interactions are made with 
IPTG by two arginines (Arg-101 and Arg-192), two aspar- 
tic acids (Asp-149 and Asp-274), an asparagine (Asp-264) 
and a serine (Ser-69). It will be of interest to see the 
interactions of this protein with a disaccharide when this 
protein is crystallized in the presence of lactose (or allolac- 
tose, the true inducer). 
9.2. A binding site for protons 
The residues in the protein responsible for binding of 
H + (or hydronium ion) have not been considered. Of the 
amino acid residues in the carrier, Glu-325 and Glu-269 
are particularly good candidates for possible coordination 
with the cation. The change of either of these two residues 
to most neutral amino acids leads to a complete loss of 
~ 3 
t s 
, 
,. 0 /  . . . .  
S-Lac Lectin Lactose Carrier 
Fig. 6. Hypothetical binding site in the lactose carrier. On the left is the lactose binding site in the S-lac lectin as determined byX-ray crystallography [64]. 
On the right is a hypothetical binding site in the lactose carrier based on analyses ofmutants ( ee text). 
M.F. Varela, T.H. Wilson/Biochimica et Biophysica Acta 1276 (1996) 21-34 33 
proton transport. Thus an important role in proton transport 
is indicated. We propose that Glu-325 (and perhaps Glu- 
269) are involved in hydronium ion binding. One cation 
binding protein (human molecular chaperone Hsc 70) which 
has been studied by X-ray crystallography [113] shows 
coordination sites to two aspartic acids (Asp-206 and 
Asp-199) plus two additional residues to the sodium ion 
while another protein (dialkylglycine decarboxylase) shows 
a coordination site for one aspartic acid (Asp-307) plus 
three additional residues for sodium ion [40]. 
We suggest hat the hydronium ion interacts with Glu- 
325 (and perhaps Glu-269) plus several other residues. The 
possibility that the hydronium ion itself provides a coordi- 
nation site for sugar binding might be considered. This 
binding of cation causes an allosteric hange which facili- 
tates the binding of the sugar. The presence of both cation 
and sugar results in an additional allosteric change which 
opens the exit channel for sugar and cation. This results in 
the transfer of one sugar molecule and one cation across 
the membrane into the cell. Further work is required to 
provide evidence for this hypothesis. 
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